214 related articles for article (PubMed ID: 28747219)
21. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
Glezerman I; Kris MG; Miller V; Seshan S; Flombaum CD
Clin Nephrol; 2009 Feb; 71(2):130-9. PubMed ID: 19203505
[TBL] [Abstract][Full Text] [Related]
22. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F; Frémeaux-Bacchi V; Loirat C
Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
[TBL] [Abstract][Full Text] [Related]
23. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Müller S; Schütt P; Bojko P; Nowrousian MR; Hense J; Seeber S; Moritz T
Ann Hematol; 2005 Feb; 84(2):110-4. PubMed ID: 15340761
[TBL] [Abstract][Full Text] [Related]
24. Hemolytic-uremic syndrome caused by gemcitabine.
Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M
Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169
[No Abstract] [Full Text] [Related]
25. [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
Wato M; Inaba T; Ishikawa H; Ishikawa S; Baba N; Miyoshi M; Senoh T; Nagano T; Takaguchi K; Watanabe S; Kawai K
Nihon Shokakibyo Gakkai Zasshi; 2010 Oct; 107(10):1676-85. PubMed ID: 20938119
[TBL] [Abstract][Full Text] [Related]
26. [Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Desramé J; Duvic C; Bredin C; Béchade D; Artru P; Brézault C; Defuentes G; Poirier JM; Dourthe LM; Coutant G; Chaussade S; de Gramont A; Algayres JP
Rev Med Interne; 2005 Mar; 26(3):179-88. PubMed ID: 15777580
[TBL] [Abstract][Full Text] [Related]
27. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
[TBL] [Abstract][Full Text] [Related]
28. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.
Vénat-Bouvet L; Ly K; Szelag JC; Martin J; Labourey JL; Genet D; Tubiana-Mathieu N
Anticancer Drugs; 2003 Nov; 14(10):829-32. PubMed ID: 14597878
[TBL] [Abstract][Full Text] [Related]
29. [Thrombotic microangiopathy under an effective treatment with gemcitabine].
Finkenwirth P; Schick D; Horger MS; Fend F; Lauer UM; Gregor M; Bitzer M
Z Gastroenterol; 2009 Mar; 47(3):288-91. PubMed ID: 19280543
[TBL] [Abstract][Full Text] [Related]
30. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
31. [Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].
Casiez C; Pica GM; Bally S
Nephrol Ther; 2020 Jul; 16(4):221-224. PubMed ID: 32571738
[TBL] [Abstract][Full Text] [Related]
32. Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.
Ritchie GE; Fernando M; Goldstein D
Cancer Chemother Pharmacol; 2017 Jan; 79(1):1-7. PubMed ID: 27497971
[TBL] [Abstract][Full Text] [Related]
33. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
[TBL] [Abstract][Full Text] [Related]
34. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.
Tschumi S; Gugger M; Bucher BS; Riedl M; Simonetti GD
Pediatr Nephrol; 2011 Nov; 26(11):2085-8. PubMed ID: 21877169
[TBL] [Abstract][Full Text] [Related]
35. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD; Bannerman F; Beresford MW; Oni L
BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
[TBL] [Abstract][Full Text] [Related]
37. [Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].
Desramé J; Duvic C; Béchade D; Bredin C; Raynaud JJ; Defuentes G; Dourthe LM; Algayres JP
Gastroenterol Clin Biol; 2006 Feb; 30(2):332-4. PubMed ID: 16565677
[No Abstract] [Full Text] [Related]
38. [Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].
Reis S; Ramos D; Cordinhã C; Gomes C
Acta Med Port; 2019 Oct; 32(10):673-675. PubMed ID: 31625881
[TBL] [Abstract][Full Text] [Related]
39. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
40. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
Kourouklaris A; Ioannou K; Athanasiou I; Panagidou A; Demetriou K; Zavros M
J Med Case Rep; 2014 Sep; 8():307. PubMed ID: 25219386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
